Many types of service providers would have to let employers audit them for signs of prescription drug rebate problems.

Notably, female GLP-1 users experienced a 47% reduction in hospitalizations for major cardiovascular events; approximately 50% lower incidence of ovarian cancer; and a 14% lower incidence of breast cancer compared to female non-users.

2026 will reward employers, brokers, and vendors that embrace flexibility, transparency, and consumer-driven benefits design — and those that help employees make smarter financial decisions in an increasingly complex health care landscape.